Treatment Challenges and Advances in Hodgkin Lymphoma: Craig Moskowitz, MD, and Kami Maddocks, MD

In this exclusive with i3 Health, Craig H. Moskowitz, MD, Professor of Medicine at the University of Miami and Physician-in-Chief at the Sylvester Comprehensive Cancer Center, and Kami Maddocks, MD, Associate Professor of Clinical Internal Medicine and Lymphoma Program Director at The James Cancer Hospital at The Ohio State University, share their perspectives on the management of relapsed/refractory classical Hodgkin lymphoma (HL) and the advances brought to the treatment of this disease by dev...
Continue reading

Why Do Pre-Immunotherapy Antibiotics Reduce Survival? With David J. Pinato, MD, MRes, PhD

​Many patients with cancer experience infections requiring treatment. However, David Pinato, MD, MRes, PhD, and colleagues recently found that in patients with non-small cell lung cancer (NSCLC), melanoma, and other tumor types, broad-spectrum antibiotic treatment administered within 30 days prior to the commencement of immune checkpoint inhibitor therapy dramatically worsened overall survival (2 vs 26 months) and increased the risk of treatment-refractory disease. In this interview with i3 Heal...
Continue reading

Pre-Immunotherapy Antibiotics Drastically Reduce Survival

An observational study reports that broad-spectrum antibiotic treatment administered within 30 days prior to the commencement of immune checkpoint inhibitor therapy dramatically worsens overall survival and increases the risk of treatment-refractory disease.Published in JAMA Oncology, the prospective cohort study conducted at two tertiary academic referral centers enrolled 196 patients with cancer receiving immune checkpoint therapy for non-small cell lung cancer (119 patients), melanoma (38 pat...
Continue reading

Immuno-Oncology and Checkpoint Inhibition in Cervical Cancer: Bradley Monk, MD, FACS, and Ramez Eskander, MD

​Unlike that of other gynecological malignancies, the etiology of cervical cancer is the human papillomavirus (HPV). This fact plays a role in how cervical cancer is perceived as immunogenic: T cells themselves are involved in the immune response and in the control of viral infections and the development of these tumors. In this discussion with i3 Health, Bradley Monk, MD, FACS, FACOG, Professor of Gynecologic Oncology at the University of Arizona and Creighton University, and Ramez Eskander, MD...
Continue reading

Survey of Oncology Nurses Reveals Knowledge Gaps Surrounding Immune Checkpoint Inhibitors

Immune checkpoint inhibition is a form of immunotherapy that blocks checkpoint proteins on immune cells, boosting the body's immune response against cancer cells. Checkpoint inhibitors such as pembrolizumab (Keytruda®, Merck), nivolumab (Opdivo®, Bristol-Myers Squibb), atezolizumab (Tecentriq®, Genentech), durvalumab (Imfinzi®, AstraZeneca), cemiplimab (Libtayo®, Regeneron Pharmaceuticals, Inc.), ipilimumab (Yervoy®, Bristol-Myers Squibb), and avelumab (Bavencio®, EMD Serono and Pfizer) have dem...
Continue reading

Copyright © 2020 i3 Health. All rights reserved.